Leerink Partnrs Increases Earnings Estimates for 908 Devices

908 Devices Inc. (NASDAQ:MASS) – Stock analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for 908 Devices in a research report issued to clients and investors on Tuesday, May 13th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings per share of ($0.20) for the quarter, up from their previous estimate of ($0.21). The consensus estimate for 908 Devices’ current full-year earnings is ($1.99) per share. Leerink Partnrs also issued estimates for 908 Devices’ FY2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.54) EPS.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of 908 Devices in a research report on Saturday, May 10th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $5.33.

908 Devices Stock Performance

908 Devices stock opened at $4.58 on Friday. 908 Devices has a fifty-two week low of $1.81 and a fifty-two week high of $7.03. The stock has a market cap of $163.69 million, a PE ratio of -2.59 and a beta of 0.26. The firm’s 50-day simple moving average is $4.60 and its 200 day simple moving average is $3.27.

908 Devices (NASDAQ:MASS) last announced its earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. The business had revenue of $11.78 million during the quarter, compared to the consensus estimate of $11.90 million. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%.

Insider Buying and Selling at 908 Devices

In other 908 Devices news, Director Mark Spoto acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were acquired at an average cost of $4.29 per share, with a total value of $42,900.00. Following the transaction, the director now owns 62,971 shares of the company’s stock, valued at $270,145.59. The trade was a 18.88% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 27.70% of the company’s stock.

Institutional Investors Weigh In On 908 Devices

Several hedge funds and other institutional investors have recently modified their holdings of MASS. Two Sigma Advisers LP purchased a new stake in 908 Devices in the 4th quarter worth $30,000. CWM LLC lifted its holdings in shares of 908 Devices by 541.2% in the 1st quarter. CWM LLC now owns 6,963 shares of the company’s stock valued at $31,000 after acquiring an additional 5,877 shares during the last quarter. Prudential Financial Inc. bought a new position in shares of 908 Devices in the 4th quarter valued at about $34,000. Occudo Quantitative Strategies LP bought a new position in shares of 908 Devices in the 4th quarter valued at about $36,000. Finally, Two Sigma Investments LP bought a new stake in 908 Devices in the fourth quarter worth about $42,000. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.